Association between renal function and cardiovascular mortality: a retrospective cohort study of elderly from health check-up

Ying-Jhen Huang,1 Yu-Lin Hsu,¹ Yung-Hsin Chuang,1,2 Hugo Y -H Lin,3,4,5 Yen-Hsu Chen,6,7,8,9 Ta-Chien Chan,1,2

ABSTRACT

Objectives This study aimed to investigate the relationship between cardiovascular mortality in elderly Asians and decline in renal function.

Design A retrospective cohort study.

Setting Community-based health examination database from Taipei city.

Participants At the beginning, the database included 315,045 health check-up visits of 97,803 elderly persons aged ≥65 years old from 2005 to 2012. After excluding missing values and outliers, there were 64,732 elderly persons with at least two visits retained for further analyses.

Primary outcome measures Kidney function indicators include estimated glomerular filtration rate (eGFR) and urine protein, and rapid decline in eGFR was defined as slope ≤ −5 mL/min/1.73 m² per year. The endpoint outcome was defined as the cardiovascular deaths registered in the death registry encoded by the International Classification of Diseases. We applied a Cox proportional hazards model to analyse the association between renal function and cardiovascular mortality.

Results In this study, we found 1,264 elderly persons died from cardiovascular diseases, for whom the data included 4,055 previous health check-up visits. We observed significant and independent associations of eGFR < 60 mL/min/1.73 m² (HR (95% CI) of 60–45 eGFR: 45 and eGFR < 45 in males: 2.85 (1.33 to 6.09) and 3.98 (1.84 to 8.61); in females: 3.66 (1.32 to 10.15) and 6.77 (2.41 to 18.99)); positive proteinuria (HR (95% CI) of +/−, ++ and ++++, +++ in males: 1.51 (1.29 to 1.78) and 2.31 (1.51 to 3.53); in females: 1.93 (1.54 to 2.42) and 4.23 (2.34 to 7.65)) and rapid decline in eGFR (HR (95% CI) in males: 3.24 (2.73 to 3.85); in females: 2.83 (2.20 to 3.64) with higher risk of cardiovascular mortality. The joint effect of increased concentration of urine protein and reduced eGFR was associated with a higher risk of cardiovascular mortality.

Conclusions Renal function and rapid decline in renal function are independent risk factors for cardiovascular mortality in the elderly.

INTRODUCTION

Chronic kidney disease (CKD) is a common disease among the elderly, and is defined as structural or functional abnormality of the kidney (glomerular filtration rate (GFR) <60 mL/min/1.73 m², albuminuria or markers of kidney damage) for 3 months or more in clinical diagnosis.1 With ageing, the structure and physiology of the kidneys change, leading to decline in the functions of waste removal, maintenance of electrolyte balance and regulation of blood pressure. Hypertension, diabetes, long-term inflammation and urological diseases (such as prostate hypertrophy and urinary tract stones) are not only common chronic diseases in the elderly, but also common causes of deterioration of renal function, and contribute to CKD progression.2 3 In addition, the elderly are a population at high risk for acute kidney injury because of physiological age-related changes or polypharmacy and drug toxicity, and probably develop CKD in the context of incomplete repair of renal tubular epithelial cells, glomerulosclerosis, ischaemia-reperfusion injury and fibrosis.5 6

Cardiovascular disease (CVD) is the leading cause of death worldwide, causing an estimated 17.8 million deaths in 2017,7 approximately 1.4 million out of all CVD deaths are attributable to impaired renal function.8
Clarifying the relationship between renal function and cardiovascular mortality is vital, so as to enable early intervention to reduce the social and medical burden. Many studies have found evidence that CKD is an independent risk factor for CVDs and cardiovascular mortality and have suggested possible mechanisms for this. A joint effect of estimated GFR (eGFR) and proteinuria on the adverse outcomes has been proposed, and it is suggested that combining the two indicators of renal function provides a better estimation for the risk of cardiovascular mortality, especially in the elderly over 70. However, there are still studies which do not support this hypothesis. Wang et al reported no significant association of the joint effect of eGFR and urinary albumin-to-creatinine ratio (ACR) with either all-cause or cardiovascular mortality among participants, non-institutionalised adults (18 years or older), of the China National Survey of CKD in China. In addition to affecting the prognosis of renal function, the magnitude of renal function decline (eGFR slope) is also related to the increased risk of cardiovascular events and cardiovascular mortality. However, to the best of our knowledge, such epidemiological studies are limited and have not yet included Asian elderly populations.

The objective of this study was to clarify the independent relationship between the risk of CVD mortality among the elderly in Taiwan and their renal function and its decline. More specifically, the present study aimed to determine whether the eGFR, proteinuria and eGFR slope are independent risk factors of cardiovascular mortality, and examine the joint effect of eGFR and urine protein to propose a combination more suitable for predicting the cardiovascular mortality risk of the elderly in Taiwan.

METHOD

Study design and ethical statement

This research was designed as a retrospective longitudinal cohort study based on an elderly health examination database. Participants were enrolled, with informed consent signed and submitted to Taipei City Government, to record health examination data for research purposes. This database is linked to Taiwan’s National Death Registry from 2005 to 2012. At the beginning, the database included 315,045 elderly persons aged ≥65 years old from 2005 to 2012. The selection process is shown in figure 1. The renal function assessed by the estimated GFR (eGFR) is one of our important explanatory variables. We used the Berlin Initiative Research calculation formula, which is more suitable for evaluating the glomerular filtration in the elderly. The formula is eGFR (mL/min/1.73 m²)=3736 × serum creatinine−0.87× (age)−0.95 × (0.82 if female). Thus, we excluded data for visits with a date of death (visits=27) and those with missing values for explanatory variables, including body mass index (BMI) (visits=639), urine protein (visits=3,339), smoking status (visits=663) and drinking status (visits=188). Furthermore, we excluded participants who had taken the health examination only once (persons=31,251) and those with erroneous data (with a date of death preceding the health check-up) (persons=8; visits=25). Finally, 64,732 elderly persons and 274,049 visits were retained for further analyses. The endpoint outcome was defined as the cardiovascular deaths registered in the death registry encoded by the ninth or tenth revision (with death year

Figure 1 Flow chart for selection of participants. BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.

Selection of participants

At the beginning, the database included 315,045 health check-up visits of 97,803 elderly persons aged ≥65 years old from 2005 to 2012. The selection process is shown in figure 1. The renal function assessed by the estimated GFR (eGFR) is one of our important explanatory variables. We used the Berlin Initiative Research calculation formula, which is more suitable for evaluating the glomerular filtration in the elderly. The formula is eGFR (mL/min/1.73 m²)=3736 × serum creatinine−0.87× (age)−0.95 × (0.82 if female). Thus, we excluded data for visits without a serum creatinine test (visits=3844). Additionally, we excluded participants with abnormal eGFR (≥200 mL/min/1.73 m²) (visits=27) and those with missing values for explanatory variables, including body mass index (BMI) (visits=1639), urine protein (visits=3359), smoking status (visits=663) and drinking status (visits=188). Furthermore, we excluded participants who had taken the health examination only once (persons=31,251) and those with erroneous data (with a date of death preceding the health check-up) (persons=8; visits=25). Finally, 64,732 elderly persons and 274,049 visits were retained for further analyses. The endpoint outcome was defined as the cardiovascular deaths registered in the death registry encoded by the ninth or tenth revision (with death year

Patient and public involvement

This study obtained secondhand data; participants did not receive feedback on the results and were not involved in the study.

Cohort description

This community-based cohort study used data from the Taipei City Elderly Health Examination Database. The study period covered 2005–2012. The Taipei City Government provides free annual elderly health examinations in Taipei City. On average, around 42,000 elderly persons each year participate in the examinations, which accounts for 13% of the registered elderly population in Taipei City. All participants received a health examination once annually.

Original dataset from 2005 to 2012
(persons=97,803; visits=3,156,045)

Exclude participants with missing information of serum creatinine (visits=3,844)

Has complete data on serum creatinine
(persons=97,936; visits=3,11,281)

Has complete data on all covariates
(persons=95,091; visits=303,325)

Death registry from 2005 to 2012 by using the participants’ identification number and personal information encrypted by the data managers. Data were stored in the Taipei Geriatric Health Examination Database, and labels were deidentified before release.

Deaths from CVD
(persons=1,564; visits=4,055)

Surviving, or deaths from other causes
(persons=83,468; visits=204,994)

Exclude participants with eGFR ≥200 mL/min/1.73 m² (visits=27)

Exclude participants with eGFR ≥200 mL/min/1.73 m² and those with missing values for explanatory variables, including body mass index (BMI) (visits=1639), urine protein (visits=3359), smoking status (visits=663) and drinking status (visits=188).

Finally, 64,732 elderly persons and 274,049 visits were retained for further analyses. The endpoint outcome was defined as the cardiovascular deaths registered in the death registry encoded by the ninth or tenth revision (with death year...
after 2009) of the International Classification of Diseases (ICD-9 or ICD-10). The ICD-9 codes are defined from 390 to 459, and the ICD-10 codes are defined in Chapter 9 (cardiovascular system) of ICD-10 (https://icd.who.int/browse10/2008/en#/IX). In this study, we found 1264 elderly persons died from CVDs (4055 visits), 4002 died from non-CVD (13014 visits) and 59466 lived until the study end (256980 visits).

Definition of explanatory variables
There are 10 explanatory variables used in the statistical analyses: (1) Age group: We coded participants aged older than 75 years old as 1, and those 65–74 years old as 0, (2) BMI: We classified BMI into six groups based on the suggestion from the Health Promotion Administration, Ministry of Health and Welfare, Taiwan (https://health99.hpa.gov.tw/OnlinkHealth/OnLink_BMI.aspx). We treated normal weight (18.5 kg/m² ≤ BMI < 24 kg/m²) as the reference group. The remaining five groups are underweight (BMI < 18.5 kg/m²), overweight (24 ≤ BMI < 27 kg/m²), slightly obese (27 ≤ BMI < 30 kg/m²), moderately obese (30 ≤ BMI < 35 kg/m²), and severely obese (BMI ≥ 35 kg/m²). (3) History of heart disease: participants who fulfilled one of three criteria, including medical history of heart disease, regularly taking medicine because of heart disease or reporting having heart disease, (4) History of hypertension: participants who fulfilled one of four criteria including high blood pressure (systolic pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg), a history of hypertension, regularly taking medicine because of hypertension, or reporting having hypertension, (5) History of diabetes: participants who fulfilled one of four criteria including high fasting glucose (≥ 126 mg/dL), a history of diabetes, regularly taking medicine because of diabetes, or reporting having diabetes, (6) Smoking status: We classified smoking status into three groups, including non-smoking (as a reference), smoking occasionally and smoking every day, (7) Drinking status: We classified drinking status into two groups, including non-drinking (as a reference) and drinking, (8) eGFR class: We classified eGFR into four groups, including eGFR ≥ 90 mL/min/1.73 m² (as a reference), 60 mL/min/1.73 m² ≤ eGFR < 90 mL/min/1.73 m², 45 mL/min/1.73 m² ≤ eGFR < 60 mL/min/1.73 m², and eGFR < 45 mL/min/1.73 m², (9) eGFR Decline: We defined this as the mean rate of change in eGFR from first (baseline) to last visit in the follow-up for each participant [eGFR slope=3736× serum creatinine−0.87× (age)−0.95× (0.82 if female)/years]. Then, eGFR decline was classified into two groups, including slope > −5 mL/min/1.73 m²/ year (as a reference) and slope ≤ −5 mL/min/1.73 m²/ year and (10) Urine protein: We classified this into three groups, including − (as a reference), (+/-, +, ++) and (+++ or ++++).

Statistical analyses
All analyses were performed with RStudio software V1.2.5033 (2009–2019 RStudio). In the survival analysis, to evaluate the effects of multiple variables on cardiovascular mortality (time to event), we applied the baseline Cox proportional hazards model. No participants in our data were lost or withdrew, so censoring only occurs when the participants died until the study end (31 December 2012) or when the participants died from causes other than the outcomes of interest. The cause-specific relative hazard and the subdistribution relative hazard approaches were used in competing risks analysis.24 The results from competing risk analysis were used as the sensitivity analysis. Since the data show the dates of death in year-month format, we input the middle day of the month as the date of death. For those participants who died in the same month as the date of the health check-up visit, we input the last day of the month as the date of death.25 The analysis was conducted separately by gender.

RESULTS
Among the included participants’ visits (table 1), the number of males (853) with cardiovascular deaths exceeded that of females (411). In the younger elderly participants (age 65–74), the females (22,675) outnumbered males (18,258). Among included participants, a much higher proportion of females were in this younger elderly group (72.68%), whereas males showed the opposite pattern. In the underweight (18.5), the females had proportions (3.96%) similar to that of the male proportions (3.90%). The proportion of males (33.86%) was larger than females (29.82%) in the overweight (24 ≤ BMI < 27) group; on the other hand, the proportions of slightly obese (27 ≤ BMI < 30), moderately obese (30 ≤ BMI < 35) and severely obese (BMI ≥ 35) were much higher in females (13.90%, 5.33%, 0.66%) than in males (12.54%, 3.52%, 0.27%). The proportions having heart diseases (25.80%) and diabetes history (27.79%) were slightly higher in males. The proportion having hypertension history in females (74.90%) was almost the same as in males (74.62%). The proportions of non-smoking (96.92%) and non-smoking (90.51%) behaviours were much higher in females. In normal eGFR (eGFR ≥ 90) and slightly mildly decreased eGFR groups (90 ≤ eGFR < 60), the proportion of females was higher (4.77%, 57.51%) than males (1.67%, 45.53%). However, in the mildly decreased eGFR group (60 ≤ eGFR < 45) and moderately decreased eGFR group (eGFR < 45), the proportion of males was higher (41.40%, 11.40%) than females (29.42%, 8.30%). The females with eGFR decline (≤ −5) had a slightly higher proportion (14.30%) than the males (12.20%). Last, a much higher proportion of females were in the normal urine protein group (−) (86.78%), whereas males showed the opposite pattern.

The results of the adjusted Cox proportional hazards model are shown in table 2. Compared with the persons with eGFR ≥ 90 mL/min/1.73 m², a significant higher risk of cardiovascular death was observed with eGFR 45–59 (male: HR: 2.85, 95% CI: 1.33 to 6.09; female: HR: 3.66, 95% CI: 1.32 to 10.15) and eGFR < 45 mL/min/1.73 m²...
Huang Y-J, et al. BMJ Open 2021;11:e049307. doi:10.1136/bmjopen-2021-049307

Open access

Table 1 Characteristics of included participants’ visits stratified by gender

| Variables                        | Male (n: 33 532) Mean±SD/counts (%) | Female (n: 31 200) Mean±SD/counts (%) | P value  |
|----------------------------------|-------------------------------------|---------------------------------------|----------|
| CVD deaths                       | 853 (2.54)                          | 411 (1.32)                            | <0.001   |
| Age                              | 65–74                               | 18 258 (54.45)                        | 22 675 (72.68) | <0.001 |
|                                  | ≥75                                 | 15 274 (45.55)                        | 8 525 (27.32) |
| BMI                              | 18.5≤BMI<24 (normal)                | 15 390 (45.90)                        | 14 452 (46.32) | <0.001 |
|                                  | BMI <18.5                           | 13 080 (3.90)                         | 12 37 (3.96) |
|                                  | 24≤BMI<27                           | 11 355 (33.86)                        | 9 305 (29.82) |
|                                  | 27≤BMI<30                           | 4 205 (12.54)                         | 4 336 (13.90) |
|                                  | 30≤BMI<35                           | 11 82 (3.52)                          | 1 664 (5.33) |
|                                  | BMI≥35                              | 92 (0.27)                             | 206 (0.66) |
| Heart disease history            |                                     | 8 651 (25.80)                         | 7 462 (23.92) | <0.001 |
| Hypertension history             |                                     | 25 023 (74.22)                        | 23 369 (74.90) | 0.424 |
| Diabetes mellitus history        |                                     | 9 317 (27.79)                         | 8 390 (26.89) | 0.111 |
| Smoking status                   |                                     |                                       |          |
| Non-smoking                      | 29 447 (87.82)                      | 30 238 (96.92)                        | <0.001   |
| Smoking occasionally             | 2 250 (6.71)                        | 586 (1.87)                            |          |
| Smoking every day                | 1 835 (5.47)                        | 377 (1.21)                            |          |
| Drinking status                  |                                     |                                       |          |
| Non-drinking                     | 24 569 (73.27)                      | 28 240 (90.51)                        | <0.001   |
| Drinking                         | 8 963 (26.73)                       | 2 960 (9.49)                          |          |
| Creatine (mg/dL)                 | 1.14±0.47                           | 0.88±0.47                             | <0.001   |
| eGFR category                    |                                     |                                       |          |
| eGFR ≥90                         | 561 (1.67)                          | 1 487 (4.77)                          | <0.001   |
| 90>eGFR≥60                       | 15 266 (45.53)                      | 1 794 (57.51)                         |          |
| 60>eGFR≥45                       | 13 882 (41.40)                      | 9 180 (29.42)                         |          |
| eGFR <45                         | 3 823 (11.40)                       | 2 590 (8.30)                          |          |
| eGFR decline                     |                                     |                                       |          |
| Slope > −5                       | 29 441 (87.80)                      | 26 739 (85.70)                        | <0.001   |
| Slope ≤ −5                       | 4 091 (12.20)                       | 4 461 (14.30)                         |          |
| Urine protein                     |                                     |                                       |          |
| −                                 | 27 513 (82.05)                      | 27 074 (86.78)                        | <0.001   |
| +/−, +, ++                       | 5 861 (16.94)                       | 3 962 (12.70)                         |          |
| ++++, ++++                       | 338 (1.01)                          | 164 (0.53)                            |          |
| No of visits                      | 4.35±2.02                           | 4.11±1.93                             | <0.001   |
| Duration of follow-up (years)    | 4.22±2.13                           | 4.04±2.10                             | <0.001   |

Continuous variables are presented as mean±SD; category variables are expressed as a count (%).

BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.

(male: HR: 3.98, 95% CI: 1.84 to 8.61; female: HR: 6.77, 95% CI: 2.41 to 18.99). The eGFR decline slope ≤ −5 (male: HR: 3.24, 95% CI: 2.73 to 3.85; female: HR: 2.83, 95% CI: 2.20 to 3.64), urine protein (+/−, +, ++, male: HR: 1.51, 95% CI: 1.29 to 1.78; female: HR: 1.93, 95% CI: 1.54 to 2.42), and urine protein (+++, ++++, male: HR: 2.31, 95% CI: 1.51 to 3.53; female: HR: 4.23, 95% CI: 2.34 to 7.65) were associated with an increased risk of cardiovascular death. Additionally, age ≥75 years and having heart disease history were independent risk factors for cardiovascular death in both genders. The association between a history of hypertension and the risk of cardiovascular death was only significant in males. Furthermore, competing risk analysis determined that eGFR <90 mL/
min/1.73m², positive proteinuria and rapid decline in eGFR were associated with an increased risk of cardiovascular mortality (online supplemental tables S1 and S2).

We stratified our participants into 12 groups based on different levels of renal function (eGFR ≥ 90, 90>eGFR≥ 60, 60>eGFR≥45, eGFR <45) and different levels of urine protein ((–), (+/−, +, ++), and (+++ or ++++)). Table 3 shows the joint effect of eGFR and urine protein with cardiovascular mortality different between genders. Compared with participants with normal renal function (eGFR ≥90 + urine protein (−)), those who met eGFR <60mL/min/1.73m² or tested positive in urine protein had a significant increase in cardiovascular mortality. When participants met both criteria, eGFR <60mL/min/1.73m² and having proteinuria, the risk of cardiovascular mortality in males and females was significantly increased by more than three and six times, respectively.

Figure 2A–C shows that the survival curves estimated by the Cox proportional hazards model depends on different levels of renal function and different levels of urine protein. The worse urine protein and worse reduction in eGFR a participant had, the lower their probability of survival. Additionally, the survival probabilities among females were higher than those among males in all groups.

**DISCUSSION**

In this cohort study, we observed significant and independent associations of a lower eGFR level, an elevated level of protein in urine, and a rapid past decline in eGFR with higher risk of cardiovascular mortality. The joint effect of increased concentration of urine protein and reduced eGFR was associated with a lower survival probability.
Decreased GFR and persistent proteinuria are markers of kidney damage, and are associated with an increased risk of cardiovascular mortality.9 12 13 Our findings indicate that testing positive for proteinuria is an independent risk factor for cardiovascular mortality in our participants, and this is more evident in females than in males. The results of this study are consistent with previous studies, although the latter were not conducted in Asian populations.26 27 The eGFR ≤ 45 mL/min/1.73 m^2 had an increased risk of cardiovascular mortality, although this was not significant in men (HR 2.13, 95% CI 0.92 to 3.27) separately.

Table 3 The joint effect of eGFR and urine protein with cardiovascular mortality

| Variables                | Male                        | Female                       |
|--------------------------|-----------------------------|------------------------------|
|                         | HR (95% CI) | P value | HR (95% CI) | P value |
| eGFR ≥ 90 + urine protein (−) | Ref         | –       | Ref         | –       |
| 90>eGFR≥60+ urine protein (−) | 1.93 (0.79 to 4.71) | 0.148 | 2.84 (0.90 to 9.00) | 0.076 |
| 60>eGFR≥45+ urine protein (−) | 2.92 (1.19 to 7.15) | 0.019 | 4.14 (1.29 to 13.3) | 0.017 |
| eGFR <45+ urine protein (−) | 3.80 (1.53 to 9.46) | 0.004 | 6.88 (2.10 to 22.5) | 0.001 |
| eGFR ≥ 90+ urine protein (+/−, +, ++) | 1.57 (0.30 to 8.08) | 0.591 | 3.27 (0.34 to 31.5) | 0.305 |
| 90>eGFR≥60+ urine protein (+/−, +, ++) | 2.85 (1.14 to 7.10) | 0.025 | 4.72 (1.44 to 15.5) | 0.011 |
| 60>eGFR≥45+ urine protein (+/−, +, +++) | 4.18 (1.68 to 10.4) | 0.002 | 7.72 (2.36 to 25.2) | <0.001 |
| eGFR <45+ urine protein (+/−, +, +++) | 6.70 (2.65 to 17.0) | <0.001 | 16.8 (5.04 to 56.1) | <0.001 |
| eGFR ≥ 90+ urine protein (+++, ++++)* | – | – | – | – |
| 90>eGFR≥60+ urine protein (+++, ++++) | 5.02 (1.53 to 16.5) | 0.008 | 7.43 (1.49 to 37.0) | 0.014 |
| 60>eGFR≥45+ urine protein (+++, ++++) | 5.71 (1.94 to 16.8) | 0.002 | 17.0 (4.03 to 71.8) | <0.001 |
| eGFR <45+ urine protein (+++, ++++) | 10.6 (3.43 to 32.68) | <0.001 | 55.9 (12.3 to 254) | <0.001 |

* Only three men were in this state, and they were merged into the group of eGFR ≥ 90+ urine protein (+/−, +, +++) for analysis.

eGFR, estimated glomerular filtration rate.

Adjusted for age, BMI, heart disease history, hypertension history, diabetes mellitus history, smoking, drinking and eGFR decline.

As far as we know, only a study by Nerpin et al has shown that the combination of urinary albumin excretion rate and cystatin C-based eGFR is beneficial to improve the prediction of cardiovascular mortality in elderly men.36 In our study, the effect of a combination of increased urine protein concentration and reduced eGFR was associated with a lower survival probability. Participants with both eGFR <60 mL/min/1.73 m^2 and positive urine protein showed a higher risk of cardiovascular mortality compared with participants with normal renal function, and this was more prominent in females than in males.

Rapid decline in renal function is a risk factor for cardiovascular mortality. Rifkin et al found an association between the change of eGFR >5 mL/min/1.73 m^2/year and elevated risk for all-cause and cardiovascular mortality in older adults.22 Sumida et al also showed that rapid decline of eGFR (slopes of <−5 mL/min/1.73 m^2/year) is associated with higher
all-cause and cardiovascular mortality in advanced CKD of veterans in the USA. To the best of our knowledge, no study provides results on gender effects, but it has been proposed that males have poor prognosis of kidney diseases. Our results suggest that the risk of cardiovascular mortality in elderly men and women who had rapid decline in renal function (eGFR decline < -5 mL/min/1.73m²/year) was, respectively, 2.24 and 1.83 times more than their counterparts.

The advantage of our study is that this is a cohort study of elderly persons in Taipei, a major city in Taiwan, which is a large and representative population. In addition, there have been only limited studies discussing cardiovascular mortality’s relationship to both renal function and the magnitude of renal function decline in elderly Asians; we contribute to filling this gap and also analysed the effect of gender. However, the limitations of our study should be noted. First, our results cannot extrapolate to the entire Asian elderly population, but the results can still be used as a reference for the generalised elderly population. Second, we were unable to obtain a better proteinuria index—ACR. ACR is calculated by dividing the concentration of urine albumin by the concentration of urine creatinine to eliminate the dilution or concentration effect caused by hydration, which is a more objective evaluation of the amount of albumin in urine. The proteinuria test in the database used a (semiquantitative) urine test strip to estimate the amount of proteinuria by valence (-, +/-, +, 2+, 3+ and 4+), which is not as accurate as the (quantitative) microalbumin test, and there were no data available on urine creatinine to calculate ACR.

Figure 2 Plots of survival curves which applied Cox proportional hazards model to estimate males’ and females’ survival depends on different levels of renal function and different levels of urine protein. (A) It shows the survival probability under different levels of renal function when the protein in urine is negative. (B) It shows the survival probability under different levels of renal function when the protein in urine is +/-, +, or ++. (C) It shows the survival probability under different levels of renal function when the protein in urine is +++ or ++++. eGFR, estimated glomerular filtration rate.
However, the urine test strip is the most common tool for preliminary screening of proteinuria. Our findings could provide an early warning to identify groups with a high risk of cardiovascular mortality.

CONCLUSIONS
With routine and simple indicators from health examinations, renal function and urine protein can be a sensitive indicator for reducing the mortality risk of the elderly.

REFERENCES
1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. *JAMA* 2019;322:1294–304.
2. Iseki K, disease Kidney (CKD) as an emerging risk factor in the elderly. In: Watanabe M, Kiyohara C, eds. Health issues and care system for the elderly. Singapore: Springer Singapore, 2019: 137–50.
3. Mallapallli M, Friedman EA, Delano BG, et al. Chronic kidney disease in the elderly: evaluation and management. *Clin Pract* 2014;11:525–35.
4. So S, Stevenson J, Lee V. Kidney diseases in the elderly. *advanced age geriatric care*. Springer. 2019: 131–44.
5. Liu BC, Tang TT, LL L. How tubular epithelial cell injury contributes to renal fibrosis. In: Liu BC, Lan HY, LL L, eds. *Renal fibroses: mechanisms and therapies*. Singapore: Springer Singapore, 2019; 233–52.
6. Chou Y-H, Huang T-M, Chu T-S. Novel insights into acute kidney injury-chronic kidney disease continuum and the role of renin-angiotensin system. *J Formos Med Assoc* 2017;116:652–9.
7. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. *Lancet* 2018;392:1736–88.
8. GBD Chronic Kidney Disease Collaboration. Global, regional, and national age-sex-specific burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet* 2020:395:709–33.
9. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073–81.
10. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. *Lancet Diabetes Endocrinol* 2015;3:514–25.
11. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;382:339–49.
12. Haillan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II study. *Arch Intern Med* 2007;167:2490–6.
13. Irie F, Iso H, Sainench T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int* 2006;69:1264–71.
14. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79:1341–52.
15. Wang J, Wang F, Liu S, et al. Reduced kidney function, albuminuria, and risks for all-cause and cardiovascular mortality in China: a population-based cohort study. *BMJ Nephrol* 2017;18:188.
16. Turin TC, Coresh J, Tonelli M, et al. Short-Term change in kidney function and risk of end-stage renal disease. *Nephrol Dial Transplant* 2012;27:3835–43.
17. Tsai C-W, Ting I-W, Yeh H-C, et al. Longitudinal change in estimated GFR among CKD patients: a 10-year follow-up study of an integrated kidney disease care program in Taiwan. *PLoS One* 2017;12:e0173843.
18. Grams ME, Sang Y, Ballew SW, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. *J Am Soc Nephrol* 2019;30:1746–55.
19 Turin TC, Jun M, James MT, et al. Magnitude of rate of change in kidney function and future risk of cardiovascular events. Int J Cardiol 2016;202:657–65.

20 Shlipak MG, Katz R, Kestenbaum B, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009;20:2925–30.

21 Sumida K, Molnar MZ, Potukuchi PK, eds. Association of slopes of estimated GFR with post-ESRD mortality in advanced CKD patients transitioning to dialysis. Mayo Clin Proc. NIH Public Access, 2016.

22 Ritkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008;168:2212–8.

23 Schaeffner ES, Ebert N, Delanaye P, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012;157:471–81.

24 Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2006;69:375–82.

25 Woods LM, Rachet B, Ellis L, et al. Full dates (day, month, year) should be used in population-based cancer survival studies. Int J Cancer 2012;131:1120–4.

26 Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000;109:1–8.

27 Zambon S, Maggi S, Zanoni S, et al. Association of single measurement of estimated glomerular filtration rate and non-quantitative dipstick proteinuria with all-cause and cardiovascular mortality in the elderly, results from the Progetto Veneto Anziani (Pro.V.A.) study. Atherosclerosis 2012;220:201–7.

28 Kon S, Konta T, Ichikawa K, et al. Association between renal function and cardiovascular and all-cause mortality in the community-based elderly population: results from the specific health check and guidance program in Japan. Clin Exp Nephrol 2018;22:346–52.

29 Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007;2:550–62.

30 Gertow J, Ng CZ, Maneme Branca RM, et al. Altered protein composition of subcutaneous adipose tissue in chronic kidney disease. Kidney Int Rep 2017;2:1208–18.

31 Liu C, Li G, Laukkanen JA, et al. Overweight and obesity are associated with cardiac adverse structure remodeling in Chinese elderly with hypertension. Sci Rep 2019;9:1–7.

32 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219–26.

33 Hellmenns ME, Lambers Heerspink HJ, Gansevoort RT, et al. High-Sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. J Hypertens 2013;31:905–12.

34 Tsiloucis G, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005;96:946–51.

35 Iorga A, Cunningham CM, Moazeni S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ 2017;8:1–16.

36 Nerpin E, Ingelsson E, Risérus U, et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011;26:2820–7.

37 Sumida K, Molnar MZ, Potukuchi PK, eds. Association of slopes of estimated glomerular filtration rate with post-end-stage renal disease mortality in patients with advanced chronic kidney disease transitioning to dialysis. Mayo Clin Proc. Elsevier, 2016.

38 Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000;11:319–29.

39 Minutolo R, Gabbai FB, Chiodini P, et al. Sex differences in the progression of CKD among older patients: pooled analysis of 4 cohort studies. Am J Kidney Dis 2020;75:30–8.

40 Eriksen BO, Ingebrigtsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006;69:375–82.

41 Levey AS, Coresh J, Balk E, et al. National kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;138:137–47.